SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
ANUBL1; BAG1; BAT3/BAG6; C1orf131; DDI1; DDI2; FAU; HERPUD1; HERPUD2; HOPS; IKBKB; ISG15; LOC391257; MIDN; NEDD8; OASL; PARK2; RAD23A; RAD23B; RPS27A; SACS; 8U SF3A1; SUMO1; SUMO2; SUMO3; SUMO4; TMUB1; TMUB2; UBA52; UBB; UBC; UBD; UBFD1; UBL4A; UBL4B; UBL7; UBLCP1; UBQLN1; UBQLN2; UBQLN3; UBQLN4; UBQLNL; UBTD1; UBTD2; UHRF1; UHRF2;
== History == Sauk City restaurateurs and husband and wife team George and Ruth Culver started their fast food careers as the owners of an A&W on Phillips Boulevard (U.S. Highway 12) in 1961. In 1968, they purchased a resort-styled restaurant at Devil's Lake called The Farm Kitchen. Their son, Craig Culver, worked for a local McDonald's right out of college in 1973. George, Ruth, their son Craig, and his wife Lea opened the first Culver's Frozen Custard and ButterBurgers in Sauk City, Wisconsin on July 18, 1984. Craig was CEO of Culver's from its inception until mid-2015.
Solanine is a glycoalkaloid poison found in species of the nightshade family within the genus Solanum, such as the potato (Solanum tuberosum). It can occur naturally in any part of the plant, including the leaves, fruit, and tubers. Solanine has pesticidal properties, and it is one of the plant's natural defenses. Solanine was first isolated in 1820 from the berries of the European black nightshade (Solanum nigrum), after which it was named. It belongs to the chemical family of saponins.
Sources: en.wikipedia.org
=== Dinoflagellates in the Adriatic Sea === The marine dinoflagellates: Prorocentrum micans, Lingulodinium polyedra, Gymnodinium sp., and Alexandrium tamarense, were collected from the Adriatic Sea during red-tide blooms and their 4-methyl sterol content was investigated. Dinosterol is the major component in P. micans, L. polyedra, and Gymnodinium strains, suggesting that dinosterol is a good biomarker because of its high abundance in most of the analyzed dinoflagellates.
== Medicine and biotechnology == Aminopeptidase has been studied for use in treating hypertension, inflammation, and some cancers. Aminopeptidase A (APA) is implicated in blood pressure regulation by converting angiotensin II to angiotensin III. APA inhibitors are being explored as potential antihypertensive agents, offering a novel approach to managing hypertension. Aminopeptidase N (APN) has been associated with the pathogenesis of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Inhibitors of APN have demonstrated anti-inflammatory effects in animal models, positioning them as potential therapeutic agents for these conditions. Several aminopeptidases, including APN, APA, and leucine aminopeptidase (LAP), are overexpressed in various cancers. Their involvement in tumor growth, invasion, and angiogenesis makes them attractive targets for cancer therapy. Aminopeptidase inhibitors have shown promise in preclinical studies as potential anticancer agents.
A third form can sometimes be encountered in which the spaces below yttrium in group 3 are left empty, such as the table appearing on the IUPAC web site, but this creates an inconsistency with quantum mechanics by making the f-block 15 elements wide (La–Lu and Ac–Lr) even though only 14 electrons can fit in an f-subshell. There is moreover some confusion in the literature on which elements are then implied to be in group 3. While the 2021 IUPAC report noted that 15-element-wide f-blocks are supported by some practitioners of a specialized branch of relativistic quantum mechanics focusing on the properties of superheavy elements, the project's opinion was that such interest-dependent concerns should not have any bearing on how the periodic table is presented to "the general chemical and scientific community". Other authors focusing on superheavy elements since clarified that the "15th entry of the f-block represents the first slot of the d-block which is left vacant to indicate the place of the f-block inserts", which would imply that this form still has lutetium and lawrencium (the 15th entries in question) as d-block elements in group 3. Indeed, when IUPAC publications expand the table to 32 columns, they make this clear and place lutetium and lawrencium under yttrium in group 3. Several arguments in favour of Sc-Y-La-Ac can be encountered in the literature, but they have been challenged as being logically inconsistent.
Sources: en.wikipedia.org
=== Adolescents, children, and infants === Full-term and premature infants are more sensitive to copper deficiency than adults. Since the fetus accumulates copper during the last 3 months of pregnancy, infants that are born prematurely have not had sufficient time to store adequate reserves of copper in their livers and therefore require more copper at birth than full-term infants. For full-term infants, the North American recommended safe and adequate intake is approximately 0.2 mg/day. For premature babies, it is considerably higher: 1 mg/day. The World Health Organization has recommended similar minimum adequate intakes and advises that premature infants be given formula supplemented with extra copper to prevent the development of copper deficiency.
Reactions to the Houthi takeover were broadly negative, with the Arab League, Gulf Cooperation Council, United Nations, and United States refusing to recognise the "constitutional declaration" and several governorates rejecting the Houthis' authority. With most political parties criticising the coup, Jamal Benomar, the UN envoy to Yemen, announced a resumption of national talks over the future of Yemen on 8 February. Benomar said the Houthis had agreed to participate in the talks. UN Secretary-General Ban Ki-moon called for Hadi to be reinstated as president. The Houthis and other factions reached a tentative agreement, announced on 20 February, to keep the House of Representatives in place despite the "constitutional declaration" dissolving it two weeks prior. The agreement also stipulated that a "people's transitional council" would be established to represent southerners, women, youth, and other political minorities. The next day, Hadi traveled to Aden, where he said all Houthi-directed actions since 21 September 2014 were invalid, and condemned the coup d'état.
Before refilling with the same solution, the syringe needle should be externally rinsed and dried with lint-free paper, without the need for an internal wash. However, when switching to a different reagent or concentration, the syringe must be thoroughly washed, flushed with ethanol or methanol, and carefully dried under vacuum-using a ThermoVac for VP-ITC or the integrated vacuum systems in other models. The sample cell should be emptied using the loading syringe and rinsed multiple times with water.
=== Oleato coffee === In February 2023, Starbucks announced it would introduce a line of coffee drinks made with extra virgin olive oil, including lattes, shaken espresso, and cold brews. This would not be a limited-time offering, but rather "'one of the biggest launches we’ve had in decades,'" according to Brady Brewer, the company's chief marketing officer. The goal was to create a new category of beverage. Unlike other drinks, this came about because of the habits of then-CEO Howard Schultz, who was introduced to consuming a teaspoon of olive oil each day by an olive oil producer he met in Sicily. The drinks were initially available in Italy and later expanded to stores in Southern California in spring 2023 and then the UK, Middle East, and Japan later the same year. After its launch, CNN reported some customers reported digestive distress after drinking the beverages. In January 2024, the company said it would introduce the beverages nationwide in the US as well as in Canada, France, and China. The Oleato beverages were permanently discontinued in November 2024.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.